The Efficacy of Levofloxacin versus Clarithromycin in Primary Quadruple Therapy for the Eradication of Helicobacter Pylori: A Prospective Randomized Controlled Clinical Trial Study
Background: Helicobacter pylori (H. pylori) infection is prevalent in the world. Resistance to antibiotics is the main reason for treatment failure. This clinical trial examined the effect of clarithromycin versus levofloxacin as the content of first line of treatment of the patients with peptic ulc...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | fas |
| Published: |
Isfahan University of Medical Sciences
2020-06-01
|
| Series: | مجله دانشکده پزشکی اصفهان |
| Subjects: | |
| Online Access: | http://jims.mui.ac.ir/index.php/jims/article/view/12768 |
| _version_ | 1797762735828631552 |
|---|---|
| author | Vahid Sebghatollahi Reyhaneh Hosseini Babak Tamizifar Mohammad Minakari Maryam Soheilipour |
| author_facet | Vahid Sebghatollahi Reyhaneh Hosseini Babak Tamizifar Mohammad Minakari Maryam Soheilipour |
| author_sort | Vahid Sebghatollahi |
| collection | DOAJ |
| description | Background: Helicobacter pylori (H. pylori) infection is prevalent in the world. Resistance to antibiotics is the main reason for treatment failure. This clinical trial examined the effect of clarithromycin versus levofloxacin as the content of first line of treatment of the patients with peptic ulcer.
Methods: In this double-blind randomized controlled clinical trial study with parallel groups, 148 infected patients by H. pylori who had been proven during endoscopic biopsy were randomly divided into two equal groups. One group was treated with the quadruple therapy of clarithromycin 500 mg BID, amoxicillin 1 g BID, bismuth subcitrate 240 mg BID, and pantazole 40 mg BID. The second group was treated with levofloxacin 500 mg QD, amoxicillin 1 g BID, bismuth subcitrate 240 mg BID, and pantazole 40 mg BID. The duration of treatment was 14 days in both groups and four weeks after treatment, the eradication rate was assessed using the stool antigen test.
Findings: The eradication rate was significantly higher using regime containing clarithromycin than that of levofloxacin [81.1%; confidence interval of 95% (95%CI): 72.2%-89.9% vs. 60.3%; 95%CI: 49.3%-72.2%; P = 0.021). The improvement in quality of life in patients treated with clarithromycin was comparable with levofloxacin (7.90 ± 5.79 vs. 9.27 ± 5.89; P = 0.18). Adverse effects were different between the groups in which bad taste was reported more frequently in clarithromycin than levofloxacin (27.0% vs. 4.3%) while epigastric pain was more in levofloxacin (7.1% vs. 2.7%).
Conclusion: The effectiveness of clarithromycin on H. pylori eradication rate was significantly higher
than levofloxacin. |
| first_indexed | 2024-03-12T19:32:41Z |
| format | Article |
| id | doaj.art-92f7e47bd2914891bf02ff3983df4993 |
| institution | Directory Open Access Journal |
| issn | 1027-7595 1735-854X |
| language | fas |
| last_indexed | 2024-03-12T19:32:41Z |
| publishDate | 2020-06-01 |
| publisher | Isfahan University of Medical Sciences |
| record_format | Article |
| series | مجله دانشکده پزشکی اصفهان |
| spelling | doaj.art-92f7e47bd2914891bf02ff3983df49932023-08-02T04:25:01ZfasIsfahan University of Medical Sciencesمجله دانشکده پزشکی اصفهان1027-75951735-854X2020-06-013856918619210.22122/jims.v38i569.127683579The Efficacy of Levofloxacin versus Clarithromycin in Primary Quadruple Therapy for the Eradication of Helicobacter Pylori: A Prospective Randomized Controlled Clinical Trial StudyVahid Sebghatollahi0Reyhaneh Hosseini1Babak Tamizifar2Mohammad Minakari3Maryam Soheilipour4Associate Professor, Department of Gastroenterology and Endoscopy, Khorshid Hospital, Isfahan University of Medical Sciences, Isfahan, IranResident, Department of Internal Medicine, Alzahra Hospital, Isfahan University of Medical Sciences, Isfahan, IranAssociate Professor, Department of Gastroenterology and Endoscopy, Khorshid Hospital, Isfahan University of Medical Sciences, Isfahan, IranProfessor, Department of Gastroenterology and Endoscopy, Khorshid Hospital, Isfahan University of Medical Sciences, Isfahan, IranAssistant Professor, Department of Gastroenterology and Endoscopy, Khorshid Hospital, Isfahan University of Medical Sciences, Isfahan, IranBackground: Helicobacter pylori (H. pylori) infection is prevalent in the world. Resistance to antibiotics is the main reason for treatment failure. This clinical trial examined the effect of clarithromycin versus levofloxacin as the content of first line of treatment of the patients with peptic ulcer. Methods: In this double-blind randomized controlled clinical trial study with parallel groups, 148 infected patients by H. pylori who had been proven during endoscopic biopsy were randomly divided into two equal groups. One group was treated with the quadruple therapy of clarithromycin 500 mg BID, amoxicillin 1 g BID, bismuth subcitrate 240 mg BID, and pantazole 40 mg BID. The second group was treated with levofloxacin 500 mg QD, amoxicillin 1 g BID, bismuth subcitrate 240 mg BID, and pantazole 40 mg BID. The duration of treatment was 14 days in both groups and four weeks after treatment, the eradication rate was assessed using the stool antigen test. Findings: The eradication rate was significantly higher using regime containing clarithromycin than that of levofloxacin [81.1%; confidence interval of 95% (95%CI): 72.2%-89.9% vs. 60.3%; 95%CI: 49.3%-72.2%; P = 0.021). The improvement in quality of life in patients treated with clarithromycin was comparable with levofloxacin (7.90 ± 5.79 vs. 9.27 ± 5.89; P = 0.18). Adverse effects were different between the groups in which bad taste was reported more frequently in clarithromycin than levofloxacin (27.0% vs. 4.3%) while epigastric pain was more in levofloxacin (7.1% vs. 2.7%). Conclusion: The effectiveness of clarithromycin on H. pylori eradication rate was significantly higher than levofloxacin.http://jims.mui.ac.ir/index.php/jims/article/view/12768helicobacter pyloriclarithromycinlevofloxacin |
| spellingShingle | Vahid Sebghatollahi Reyhaneh Hosseini Babak Tamizifar Mohammad Minakari Maryam Soheilipour The Efficacy of Levofloxacin versus Clarithromycin in Primary Quadruple Therapy for the Eradication of Helicobacter Pylori: A Prospective Randomized Controlled Clinical Trial Study مجله دانشکده پزشکی اصفهان helicobacter pylori clarithromycin levofloxacin |
| title | The Efficacy of Levofloxacin versus Clarithromycin in Primary Quadruple Therapy for the Eradication of Helicobacter Pylori: A Prospective Randomized Controlled Clinical Trial Study |
| title_full | The Efficacy of Levofloxacin versus Clarithromycin in Primary Quadruple Therapy for the Eradication of Helicobacter Pylori: A Prospective Randomized Controlled Clinical Trial Study |
| title_fullStr | The Efficacy of Levofloxacin versus Clarithromycin in Primary Quadruple Therapy for the Eradication of Helicobacter Pylori: A Prospective Randomized Controlled Clinical Trial Study |
| title_full_unstemmed | The Efficacy of Levofloxacin versus Clarithromycin in Primary Quadruple Therapy for the Eradication of Helicobacter Pylori: A Prospective Randomized Controlled Clinical Trial Study |
| title_short | The Efficacy of Levofloxacin versus Clarithromycin in Primary Quadruple Therapy for the Eradication of Helicobacter Pylori: A Prospective Randomized Controlled Clinical Trial Study |
| title_sort | efficacy of levofloxacin versus clarithromycin in primary quadruple therapy for the eradication of helicobacter pylori a prospective randomized controlled clinical trial study |
| topic | helicobacter pylori clarithromycin levofloxacin |
| url | http://jims.mui.ac.ir/index.php/jims/article/view/12768 |
| work_keys_str_mv | AT vahidsebghatollahi theefficacyoflevofloxacinversusclarithromycininprimaryquadrupletherapyfortheeradicationofhelicobacterpyloriaprospectiverandomizedcontrolledclinicaltrialstudy AT reyhanehhosseini theefficacyoflevofloxacinversusclarithromycininprimaryquadrupletherapyfortheeradicationofhelicobacterpyloriaprospectiverandomizedcontrolledclinicaltrialstudy AT babaktamizifar theefficacyoflevofloxacinversusclarithromycininprimaryquadrupletherapyfortheeradicationofhelicobacterpyloriaprospectiverandomizedcontrolledclinicaltrialstudy AT mohammadminakari theefficacyoflevofloxacinversusclarithromycininprimaryquadrupletherapyfortheeradicationofhelicobacterpyloriaprospectiverandomizedcontrolledclinicaltrialstudy AT maryamsoheilipour theefficacyoflevofloxacinversusclarithromycininprimaryquadrupletherapyfortheeradicationofhelicobacterpyloriaprospectiverandomizedcontrolledclinicaltrialstudy AT vahidsebghatollahi efficacyoflevofloxacinversusclarithromycininprimaryquadrupletherapyfortheeradicationofhelicobacterpyloriaprospectiverandomizedcontrolledclinicaltrialstudy AT reyhanehhosseini efficacyoflevofloxacinversusclarithromycininprimaryquadrupletherapyfortheeradicationofhelicobacterpyloriaprospectiverandomizedcontrolledclinicaltrialstudy AT babaktamizifar efficacyoflevofloxacinversusclarithromycininprimaryquadrupletherapyfortheeradicationofhelicobacterpyloriaprospectiverandomizedcontrolledclinicaltrialstudy AT mohammadminakari efficacyoflevofloxacinversusclarithromycininprimaryquadrupletherapyfortheeradicationofhelicobacterpyloriaprospectiverandomizedcontrolledclinicaltrialstudy AT maryamsoheilipour efficacyoflevofloxacinversusclarithromycininprimaryquadrupletherapyfortheeradicationofhelicobacterpyloriaprospectiverandomizedcontrolledclinicaltrialstudy |